Why the study?
Low socioeconomic status is associated with higher MACE risk after incident ACS, but whether non-persistence with antiplatelet and statin therapy mediates this inequality was unclear.
Does non-persistence with antiplatelet and statin therapy mediate the income- and educational-related inequality in risk of MACE in patients with incident ACS?
Does non-persistence with antiplatelet and statin therapy mediate the income- and educational-related inequality in risk of MACE in patients with incident ACS?
Medication non-persistence partially mediates the higher risk of MACE observed in low-income men following incident ACS, highlighting a potential actionable target to reduce socioeconomic health disparities.
Non-persistence may mediate SES-related post-ACS MACE disparities; leaves open whether adherence interventions narrow gaps.
AIM: Low socioeconomic status is associated with higher risk of major adverse cardiovascular events (MACE) among patients with incident acute coronary syndrome (ACS). We examined whether non-persistence with antiplatelet and statin therapy mediated the income- and educational-related inequality in risk of MACE. METHODS: Using national registers, all Danish patients diagnosed with incident ACS from 2010 to 2017 were identified. The primary outcome (MACE) comprised all-cause death, cardiac death and cardiac readmission. Risk of MACE was handled by discrete time analyses using inverse probability of treatment weights. The mediator variable comprised non-persistence to a combined 2-dimensional measure of statin and antiplatelet treatment. The mediation analysis was evaluated by population average effects. RESULTS: The study population was 45,874 patients, of whom 16,958 (37.0%) were non-persistent with medication and 16,365 (35.7%) suffered MACE during the median follow-up of 3.5 years. Compared to patients with low income, the adjusted hazard ratio of MACE was lowered by 33% (HR: 0.67, 95% CI: 0.61-0.72) in men and by 34% (HR: 0.66, 95% CI: 0.61-0.72) in women with high income, respectively. Similar results were observed according to level of education. A socioeconomic difference in risk of non-persistence was found in men but not women and only in relation to income. The lower risk of non-persistence observed in high-income men mediated the lower risk of MACE by 12.6% (95% CI: 11.1-14.1%) compared with low-income men. CONCLUSION: Non-persistence with medication mediated some of the income-related inequality in risk of MACE in men, but not women, with incident ACS.
No takes yet. Share an insight, caveat, or question.
Graversen et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: